PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.\', \'Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel.\', \'Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.\', \'Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.\', \'Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel. yosef.shaul@weizmann.ac.il.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41598-022-09664-1
?:hasPublicationType
?:journal
  • Scientific reports
is ?:pmid of
?:pmid
?:pmid
  • 35388061
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.533
?:rankingScore_hIndex
  • 122
is ?:relation_isRelatedTo_publication of
?:title
  • Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35388061>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35388061>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all